150 related articles for article (PubMed ID: 36331867)
1. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1).
Janssen BV; van Roessel S; van Dieren S; de Boer O; Adsay V; Basturk O; Brosens L; Campbell F; Chatterjee D; Chou A; Doglioni C; Esposito I; Feakins R; Fuchs TL; Fukushima N; Gill AJ; Hong SM; Hruban RH; Kaplan J; Krasinkas A; Luchini C; Shi C; Singhi A; Thompson E; Velthuysen MF; Besselink MG; Verheij J; Wang H; Verbeke C; Fariña A;
Br J Surg; 2022 Dec; 110(1):67-75. PubMed ID: 36331867
[TBL] [Abstract][Full Text] [Related]
2. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review.
van Roessel S; Janssen BV; Soer EC; Fariña Sarasqueta A; Verbeke CS; Luchini C; Brosens LAA; Verheij J; Besselink MG
Br J Surg; 2021 Mar; 108(2):119-127. PubMed ID: 33711148
[TBL] [Abstract][Full Text] [Related]
3. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.
N Kalimuthu S; Serra S; Dhani N; Hafezi-Bakhtiari S; Szentgyorgyi E; Vajpeyi R; Chetty R
J Clin Pathol; 2017 Mar; 70(3):237-243. PubMed ID: 27681847
[TBL] [Abstract][Full Text] [Related]
4. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
5. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
Karamitopoulou E; Thies S; Zlobec I; Ott K; Feith M; Slotta-Huspenina J; Lordick F; Becker K; Langer R
Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
[TBL] [Abstract][Full Text] [Related]
6. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach.
Chou A; Ahadi M; Arena J; Sioson L; Sheen A; Fuchs TL; Pavlakis N; Clarke S; Kneebone A; Hruby G; Sahni S; Mittal A; Samra J; Gill AJ
Am J Surg Pathol; 2021 Mar; 45(3):394-404. PubMed ID: 33074853
[TBL] [Abstract][Full Text] [Related]
7. Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer.
Yuan P; Guo C; Li L; Ling Y; Guo L; Ying J
BMC Med; 2022 Oct; 20(1):403. PubMed ID: 36280845
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study.
Karamitopoulou E; Esposito I; Zlobec I; Insilla AC; Wartenberg M; Schaeffer DF; Kalloger S; La Rosa S; Sempoux C; Ramos Centeno I; Lohneis P
Virchows Arch; 2021 Apr; 478(4):719-726. PubMed ID: 33330964
[TBL] [Abstract][Full Text] [Related]
9. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
Dacic S; Travis W; Redman M; Saqi A; Cooper WA; Borczuk A; Chung JH; Glass C; Lopez JM; Roden AC; Sholl L; Weissferdt A; Posadas J; Walker A; Zhu H; Wijeratne MT; Connolly C; Wynes M; Bota-Rabassedas N; Sanchez-Espiridion B; Lee JJ; Berezowska S; Chou TY; Kerr K; Nicholson A; Poleri C; Schalper KA; Tsao MS; Carbone DP; Ready N; Cascone T; Heymach J; Sepesi B; Shu C; Rizvi N; Sonett J; Altorki N; Provencio M; Bunn PA; Kris MG; Belani CP; Kelly K; Wistuba I;
J Thorac Oncol; 2023 Oct; 18(10):1290-1302. PubMed ID: 37702631
[TBL] [Abstract][Full Text] [Related]
10. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
[TBL] [Abstract][Full Text] [Related]
11. Interobserver variation in the reporting of local peritoneal involvement and extramural venous invasion in colonic cancer.
Littleford SE; Baird A; Rotimi O; Verbeke CS; Scott N
Histopathology; 2009 Oct; 55(4):407-13. PubMed ID: 19817891
[TBL] [Abstract][Full Text] [Related]
12. Automatic cellularity assessment from post-treated breast surgical specimens.
Peikari M; Salama S; Nofech-Mozes S; Martel AL
Cytometry A; 2017 Nov; 91(11):1078-1087. PubMed ID: 28976721
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma.
Kameyama A; Ye J; Shimomura A; Yokohira M; Nakano-Narusawa Y; Yamakawa K; Mukai Y; Sanomura T; Okuyama H; Miyatake N; Furihata M; Tanaka C; Kitazawa R; Bando Y; Suemitsu Y; Kojima M; Mino-Kenudson M; Suzuki Y; Okano K; Matsuda Y
Pancreatology; 2021 Dec; 21(8):1506-1515. PubMed ID: 34563448
[TBL] [Abstract][Full Text] [Related]
14. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A
Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
[TBL] [Abstract][Full Text] [Related]
15. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
[TBL] [Abstract][Full Text] [Related]
16. Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
O'Loughlin M; Andreu X; Bianchi S; Chemielik E; Cordoba A; Cserni G; Figueiredo P; Floris G; Foschini MP; Heikkilä P; Kulka J; Liepniece-Karele I; Regitnig P; Reiner A; Ryska A; Sapino A; Shalaby A; Stovgaard ES; Quinn C; Walsh EM; Zolota V; Glynn SA; Callagy G
Breast Cancer Res Treat; 2018 Aug; 171(1):1-9. PubMed ID: 29774470
[TBL] [Abstract][Full Text] [Related]
17. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
[TBL] [Abstract][Full Text] [Related]
18. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
Wu TT; Chirieac LR; Abraham SC; Krasinskas AM; Wang H; Rashid A; Correa AM; Hofstetter WL; Ajani JA; Swisher SG
Am J Surg Pathol; 2007 Jan; 31(1):58-64. PubMed ID: 17197919
[TBL] [Abstract][Full Text] [Related]
19. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.
Van Bockstal MR; François A; Altinay S; Arnould L; Balkenhol M; Broeckx G; Burguès O; Colpaert C; Dedeurwaerdere F; Dessauvagie B; Duwel V; Floris G; Fox S; Gerosa C; Hastir D; Jaffer S; Kurpershoek E; Lacroix-Triki M; Laka A; Lambein K; MacGrogan GM; Marchiò C; Martin Martinez MD; Nofech-Mozes S; Peeters D; Ravarino A; Reisenbichler E; Resetkova E; Sanati S; Schelfhout AM; Schelfhout V; Shaaban A; Sinke R; Stanciu-Pop CM; van Deurzen CHM; Van de Vijver KK; Van Rompuy AS; Vincent-Salomon A; Wen HY; Wong S; Bouzin C; Galant C
Mod Pathol; 2021 Dec; 34(12):2130-2140. PubMed ID: 34218258
[TBL] [Abstract][Full Text] [Related]
20. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
